Clinical trials: GnRH Antagonist
Prostate Cancer
Safety and Efficacy of TAK-385 for Patients With Localized Prostate Cancer
The purpose of this study is to evaluate the efficacy of TAK-385 for achieving and maintaining testosterone suppression.
- Trial name
- NCT02135445
- Testing
- TAK-385, Degarelix
- Where
- 25 sites in United States, United Kingdom
- Volunteers
- 103 people
- Sponsor
- Millennium Pharmaceuticals, Inc.
Adenomyosis of Uterus, Implantation Failure
Linzagolix in Adenomyosis and Recurrent Implantation Failure
Adenomyosis is associated with impaired endometrial receptivity and reduced implantation rates in assisted reproduction, even when using high-quality embryos.
- Conditions
- Adenomyosis of Uterus, Implantation Failure, Infertility Female, Embryo Transfer
- Trial name
- LINZA-RIF (NCT07698561)
- Testing
- Linzagolix 200 mg (Yselty)
- Where
- 3 sites in Spain
- Volunteers
- 30 people
- Sponsor
- Vida Fertility Institute
Prostate Cancer
A Phase 2 Study to Evaluate the Safety and Efficacy of TAK-385, Together With a Leuprorelin Observational Cohort, in Participants With Prostate Cancer
The purpose of this study is to evaluate the efficacy of TAK 385 for achieving and maintaining testosterone suppression (<50 ng/dL).
- Trial name
- NCT02083185
- Testing
- Relugolix, Leuprorelin
- Where
- 23 sites in United States, Canada
- Volunteers
- 136 people
- Sponsor
- Millennium Pharmaceuticals, Inc.
Healthy
A Study of Parenterally-administered Teverelix TFA in Healthy Male Volunteers
A Phase I, open-label, single centre study investigating the pharmacokinetics, safety and pharmacodynamics of a single dose of teverelix TFA, a gonadotrophin releasing hormone antagonist, via subcutaneous or intramuscular route…
- Trial name
- NCT03781947
- Testing
- teverelix TFA
- Where
- United Kingdom
- Volunteers
- 48 people, healthy volunteers welcome
- Sponsor
- Antev Ltd.
Prostate Cancer
A Dose Finding Study of Debio 4228 in Participants With Advanced Prostate Cancer
The primary purpose of this study is to determine the pharmacokinetics (PK) and pharmacodynamics (PD) of Debio 4228.
- Trial name
- NCT06395753
- Testing
- Debio 4228
- Where
- 21 sites in United States, France and 1 more
- Volunteers
- 55 people
- Sponsor
- Debiopharm International SA
Prostatic Adenoma
Teverelix Evaluated in Advanced Prostate Cancer
The purpose of this study is to assess the safety and efficacy of teverelix TFA in the treatment of advanced prostate cancer
- Trial name
- TEACh (NCT04693507)
- Testing
- teverelix TFA 120 mg, teverelix TFA 180 mg
- Where
- 4 sites in Lithuania
- Volunteers
- 50 people
- Sponsor
- Antev Ltd.
Endometriosis
Global Study to Evaluate the Long-Term Safety and Efficacy of Elagolix in Women With Moderate to Severe Endometriosis-associated Pain
A randomized study evaluating the continued safety and efficacy of elagolix in the management of moderate to severe endometriosis associated pain in adult pre-menopausal women who completed 6 months treatment in pivotal Study…
- Trial name
- NCT02143713
- Testing
- Elagolix
- Volunteers
- 496 people
- Sponsor
- AbbVie
Infertility
MENOPUR® Versus FOLLISTIM®
To compare the efficacy and safety of highly purified menotropin (Menopur®) with that of follitropin beta (FOLLISTIM®) in patients who are undergoing gonadotropin-releasing hormone (GnRH) antagonist in vitro fertilization (IVF)…
- Trial name
- NCT00802360
- Testing
- Menotropin, Progestrone vaginal insert, follitropin beta
- Where
- 7 sites in United States
- Volunteers
- 173 people
- Sponsor
- Ferring Pharmaceuticals
Prostate Cancer
A Trial Comparing Cardiovascular Safety of Degarelix Versus Leuprolide in Patients With Advanced Prostate Cancer and Cardiovascular Disease
The purpose of this trial is to test if a marketed drug for advanced prostate cancer (FIRMAGON) can reduce the risk of cardiovascular complications as compared to another marketed drug for advanced prostate cancer (LUPRON DEPOT)…
- Trial name
- PRONOUNCE (NCT02663908)
- Testing
- Degarelix, Leuprolide
- Where
- 133 sites in United States, Canada and 10 more
- Volunteers
- 545 people
- Sponsor
- Ferring Pharmaceuticals
Advanced Prostate Cancer, GnRH Antagonist
A Study Investigating the Pharmacokinetics, Pharmacodynamics, Efficacy and Safety of Teverelix DP, a Gonadotropin-releasing Hormone (GnRH) Antagonist, in Patients With Advanced Prostate Cancer
The purpose of this clinical trial is to test the effectiveness of a dosing regimen of Teverelix DP castration rate defined as the cumulative probability of testosterone suppression to < 0.5 ng/mL with the lower bound of the 95%…
- Trial name
- NCT07457164
- Testing
- Teverelix DP 180 mg
- Volunteers
- 40 people
- Sponsor
- Antev Ltd.
In Vitro Fertilization
Corifollitropin Alfa in Participants Undergoing Repeated Controlled Ovarian Stimulation (COS) Cycles Using a Multiple Dose Gonadatropin Releasing Hormone (GnRH) Antagonist Protocol (Study 38825)(P05714)
The objective of the trial is to assess the non-immunogenicity and safety of corifollitropin alfa (also known as Org 36286, SCH 900962 and MK-8962) in participants undergoing repeated COS cycles using a multiple dose GnRH…
- Trial name
- Trust (NCT00696878)
- Testing
- Corifollitropin alfa, FSH, GnRH antagonist
- Volunteers
- 682 people
- Sponsor
- Organon and Co
Sterility
Comparative Assessment of the Clinical Utility of Ovarian Stimulation With Menotropin Versus Menotropin Plus GnRH Antagonist
To assess the effectiveness of protocols of ovarian hyperstimulation combining urinary gonadotrophins + GnRH antagonist vs urinary gonadotrophins, to achieve clinical pregnancy in females undergoing intrauterine insemination.
- Trial name
- PROMENIA (NCT01331733)
- Testing
- hMG-HP, hMG + GnRH antagonist
- Where
- 7 sites in Spain
- Volunteers
- 131 people
- Sponsor
- Ferring Pharmaceuticals
Endometriosis
A Phase II Randomized Open Label Study of KLH-2109 in Patients With Endometriosis
The purpose of this study is to evaluate the efficacy and safety of KLH-2109 in patients with endometriosis.
- Trial name
- NCT01629420
- Testing
- KLH-2109
- Where
- Japan
- Volunteers
- 20 people
- Sponsor
- Kissei Pharmaceutical Co., Ltd.
Infertility, Female
Follitropin Delta in Long GnRH Agonist and GnRH Antagonist Protocols (BEYOND)
To compare the efficacy and safety of FE 999049 (follitropin delta) and its personalized dosing algorithm in controlled ovarian stimulation for in vitro fertilization (IVF)/intracytoplasmic sperm injection (ICSI) using a long…
- Trial name
- BEYOND (NCT03809429)
- Testing
- FE 999049 + GnRH agonist (GONAPEPTYL), FE 999049 + GnRH antagonist (CETROTIDE)
- Where
- 16 sites in Austria, Denmark and 5 more
- Volunteers
- 437 people
- Sponsor
- Ferring Pharmaceuticals
Infertility
Predictive Factors for Ovarian Stimulation Using a Fixed Daily Dose of 200 IU Recombinant FSH (Study 142003)(P05696)
The success of assisted reproductive technologies (ART) is critically dependent on optimizing protocols for controlled ovarian stimulation to provide adequate numbers of good quality oocytes and embryos.
- Trial name
- Xpect (NCT00778999)
- Testing
- Marvelon
- Volunteers
- 442 people, healthy volunteers welcome
- Sponsor
- Organon and Co
Endometriosis
A Global Phase 3 Study to Evaluate the Safety and Efficacy of Elagolix in Subjects With Moderate to Severe Endometriosis-Associated Pain
A randomized study evaluating the safety and efficacy of elagolix in the management of moderate to severe endometriosis-associated pain in adult premenopausal female subjects.
- Trial name
- ELARIS EM-II (NCT01931670)
- Testing
- Elagolix
- Volunteers
- 815 people
- Sponsor
- AbbVie